Scientists from Argentina evaluated the effect of Sputnik V six months after vaccination. They found that the neutralizing strength of antibodies that is produced after vaccination only increases over time. It is reported by Interfax with reference to the Russian Direct Investment Fund (RDIF).
The researchers analyzed the number of antibodies and their ability to neutralize coronavirus infection and its variants on 1.8 thousand blood serum samples of people vaccinated with Sputnik V. Samples were received between January and August 2021.
The researchers also analyzed the drug’s effectiveness against various COVID-19 variants that are found in Argentina. It turned out that antibodies are able to block the infection caused by the “delta plus” strain.
At the moment, about 60 countries have registered the Russian vaccine. In addition to Russia, vaccine production is underway or is being prepared in Hungary, Brazil, Kazakhstan, Belarus, Slovakia, Argentina, India, South Korea, China, Germany, Italy and Egypt.
Earlier, the Indonesian authorities approved the Russian Sputnik V coronavirus vaccine for emergency use. The head of the country’s Food and Drug Administration, Penny Lukito, stressed that the vaccine has passed all the necessary tests before being approved. According to her, the effectiveness of the vaccine in preventing infection with coronavirus infection is more than 91 percent. Indonesia became the 70th country in the world to register a Russian drug for COVID-19.
On July 1, employees of the laboratory of biological agents and reagents Birmex said that in Mexico they will begin to produce the Russian vaccine against coronavirus “Sputnik V” from an active component. “At the initial stage, we can produce about 7 million doses of Sputnik V vaccine per month, and the production is expected to reach 20 million doses per month,” said laboratory director Pedro Centeno.
The Republic of the Philippines also approved the use of the Russian single-component vaccine Sputnik Light as part of an accelerated procedure.
The European Union explained the reason for the delay in the approval of the Russian vaccine against the Sputnik V coronavirus. The head of the European Commission (EC) Ursula von der Leyen noted that the European Medicines Agency (EMA) currently does not have enough convincing data to register a Russian drug. Ursula von der Leyen noted that the application to the European regulator had been submitted a long time ago. The situation “raises questions,” she added.
In June, Spanish Prime Minister Pedro Sanchez called on to allow those vaccinated with Sputnik V to enter the European Union.
Italian Prime Minister Mario Draghi, in turn, said that the approval of the Russian Sputnik V vaccine in the EU was under threat. He believes the EU may never approve the Russian drug.
In July, Kremlin spokesman Dmitry Peskov said that Russian vaccines are quite effective even against new strains of COVID-19. He expressed confidence that if political and lobbying prejudices were removed, the Russian vaccine would be recognized in the EU.
On August 20, the Russian Direct Investment Fund (RDIF) disclosed the results of clinical trials of a combination of vaccines against the coronavirus AstraZeneca and Sputnik Light in Azerbaijan.
According to preliminary data, the first 20 participants in the studies noted the development of antibodies to the spike protein (S-protein) of the SARS-CoV-2 virus.
In Argentina, with the assistance of RDIF, a study was also carried out on combinations of a Russian vaccine with a drug from the American company Moderna. According to the Deputy Minister of Health of Buenos Aires Daniel Ferrante, the study showed a good result.
Four drugs for vaccination against coronavirus are currently registered in Russia: Sputnik V, Sputnik Light, EpiVacCorona and KoviVak.
The Belgorod Region came out on top in terms of the proportion of those vaccinated with one dose of vaccine and fully vaccinated. In the region, 38.16 percent of the population is fully vaccinated. At the same time, the region is also in first place in terms of vaccination with at least one component: the first injection was made by 45 percent of the population – 686.6 thousand people. The three leaders also included the Moscow region: 32.43 percent of the region’s population received both vaccinations there. Moscow ranked ninth with an indicator of 28.45 percent.